The Zhitong Finance App learned that Morgan Stanley released a research report saying that Shiyao Group (01093) sales of proprietary medicines in the third quarter were slightly higher than expected, and there are several pipeline catalysts in the future to reinforce the bank's investment arguments. The bank maintains the “increase in holdings” rating of CSPC and the target price of HK$12.
Damo pointed out that the company aims to maintain positive growth in sales of proprietary drugs in 2027. Enbip (NBP, National Procurement) did not reduce prices, and Ming Fu is happy to reduce the price of the national health insurance catalogue by about 9%. In total, there are more than 10 innovative drugs. Sales of proprietary medicines in the third quarter increased 10% year on year and 2.5% from quarter to quarter. Among them, central nervous system (CNS) drugs increased 32% year over year, cancer drugs fell 23%, anti-infective drugs rose 2%, cardiovascular drugs fell 15%, respiratory medicines fell 15%, digestive drugs increased 41%, and other drugs fell 2%.
Business development revenue for the third quarter was RMB 373 million, and business development revenue for the first nine months of 2026 was RMB 6.3 billion, including some down payments and milestones for the AstraZeneca long-acting peptide platform and Nectin-4 ADC. The gross margin for the third quarter rose 1 percentage point year on year to 67%, the sales and administrative expenses ratio for proprietary drug sales fell 6 percentage points, the R&D ratio stabilized roughly at 31%, and adjusted net profit for the third quarter increased 39% year on year.
According to the bank, the next catalysts include the release of EGFR ADC second-line EGFR mutant non-small cell lung cancer phase 3 readings in early December by ESMO Asia, and early persistence data and potential global updates for PD-1/IL-15 in 2027.